PFIZER
Pfizer
Each stock's 10,000-path forecast, rendered as light.
Pfizer (PFIZER) Stock Analysis & Case Study
Is PFIZER a good buy? The data-driven verdict.
Pfizer (PFIZER) trades at ₹4,463,on the numbers it mixed signals, a Downstox Snapshot Score of 46/100.
On the numbers, Pfizer (PFIZER) mixed signals, a Downstox Snapshot Score of 46/100, weighing expensive at 133.0× earnings, ROE of 19.8%, a 43% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
PFIZER fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is PFIZER overvalued? PFIZER P/E vs its sector
PFIZER's P/E of 133.0× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 1.68% dividend yield is above the peer median of 1.67%.
PFIZER share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of PFIZER history (-1%/yr drift, 27%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| PFIZER 2027 | ₹3,049 | ₹4,325 | ₹6,113 | -5% |
| PFIZER 2028 | ₹2,514 | ₹4,134 | ₹6,753 | -9% |
| PFIZER 2029 | ₹2,162 | ₹3,921 | ₹7,190 | -14% |
| PFIZER 2030 | ₹1,858 | ₹3,724 | ₹7,582 | -18% |
| PFIZER 2031 | ₹1,629 | ₹3,570 | ₹7,805 | -21% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability PFIZER goes up, or doubles?
The bull case for PFIZER
- High return on equity (19.8%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (27.2%) shows the core business earns well above its cost of capital.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹7,190.
The bear case & risks
- A rich 133.0× P/E leaves a thin margin of safety if growth slows.
- A steep 14.8× price-to-book means most of the value is intangible/expectations, not assets on the books.
- The probability model is cautious 12 months out, only a 43% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹2,162.
PFIZER volatility & expected range, how bumpy is the ride?
Over the last 2.0 years PFIZER compounded at -1%/year with annualized volatility of 27%. That volatility implies a 1-year 80% range of ₹3,049–₹6,113, the honest backbone behind any single price target.
PFIZER price forecast, the full 60-month probability fan
PFIZER price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds PFIZER hits common targets within the simulated horizon?
Full multi-horizon detail on the PFIZER price target & forecast page.
PFIZER Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. PFIZER scores 4/9,mixed financial health.
PFIZER MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy PFIZER with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 27.6% | 3.6× |
| ZerodhaCHEAPEST | 27.6% | 3.6× |
| DhanCHEAPEST | 27.6% | 3.6× |
Compare every broker on the PFIZER MTF page.
PFIZER vs peers,sector comparison
About Pfizer: sector, index & market-cap context
Pfizer (PFIZER) is a mid-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹20,433 Cr. See more Nifty 200 stocks.
How the PFIZER Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Pfizer's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
PFIZER analysis, FAQs
Is Pfizer (PFIZER) a good buy?
On the numbers, Pfizer (PFIZER) mixed signals, a Downstox Snapshot Score of 46/100, weighing expensive at 133.0× earnings, ROE of 19.8%, a 43% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is PFIZER overvalued or undervalued?
PFIZER trades at 133.0× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the PFIZER share price target for 2031?
PFIZER's probability-weighted 2031 median target is ₹3,570, with an 80% range of ₹1,629–₹7,805 (10,000-path Monte-Carlo).
What is the probability PFIZER doubles in 5 years?
The modelled probability of PFIZER reaching ₹9,067 (2×) within 5 years is 6%.
What is the bull case for PFIZER?
High return on equity (19.8%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (27.2%) shows the core business earns well above its cost of capital.
What are the risks in PFIZER?
A rich 133.0× P/E leaves a thin margin of safety if growth slows. A steep 14.8× price-to-book means most of the value is intangible/expectations, not assets on the books. The probability model is cautious 12 months out, only a 43% chance of finishing above today's price.